RESUMO
Serum PSA was measured by radioimmunoassay in 52 patients with cancer prostate, 22 patients with regionally confined disease and 30 patients with [stage D2] advanced lesion. The results indicated that there was no significant difference between normal range of serum PSA and the group of patients, remained disease free during follow-up period. On the contrary, patients relapsed after initial treatment showed highly significant elevation of PSA in relation to the normal range [P >0.001]. There was also significant risk between elevated PSA level and disease progression in advanced diseases [stage D2] patients. The results indicate that PSA is a valuable marker in patients with prostate cancer not only diagnostic but also as prognostic indicator